Dr. Rajanikanth Vangala

(CEO-Neuome Technologies (P). Ltd, India, Co-Founder Neuome Peptides (P), Ltd, Singapore. Ph.D Human Biology-LMU Munich Germany, PDF-Karolinska Institute Sweden, Scientist-Hammersmith Hospital Imperial College London UK)

Ā Dr Rajani completed his Ph.D from Department of Medicine III, Klinikum Grosshardern, LMU, Munich, and post-doctoral work at the Center for Genomics and Bioinformatics, Karolinska Institute, Stockholm, as well as holding a senior research position at Hammersmith Hospital, Department of Hematology, Imperial College London.


Ludwig-Maximilians-UniversitƤt MĆ¼nchen
Ph.D, Biotechnology,
1999 – 2002

University of Hyderabad,
MSc, Biotechnology,
1996 – 1997


  • Co-Founder and CEO , Neuome Technologies Private Limited
    April 2020-Present
  • Founder Director,
    Institute for Applied Research and Innovation (InARI)
    Head Translational Research, Thrombosis Research Institute, Bangalore, Jan 2011-Feb 2018
  • Applied Biotechnology - Faculty Scientist,
    Institute of Bioinformatics and Applied Biotechnology
    Aug 2010 - Jun 2011
  • Managing Director
    InnovoBiologicals Pvt. Ltd
    Nov 2008 - Dec 2010


  1. The myeloid master regulator transcription factor PU. 1 is inactivated by AML1-ETO in t (8; 21) myeloid leukemia RK Vangala, MS Heiss-Neumann, JS Rangatia, SM Singh, C Schoch, … Blood 101 (1), 270-277, 2003
  2. The myeloid master regulator Pu. 1 is inactivated by Aml1-eto in t (8; 21) myeloid leukemia RK Vangala, MS Neumann, JS Rangatia, SM Singh, C Schoch, DG Tenen, … Onkologie 25, 262, 2002
  3. Granulocyte inducer C/EBPĪ± inactivates the myeloid master regulator PU. 1: possible role in lineage commitment decisions VA Reddy, A Iwama, G Iotzova, M Schulz, A Elsasser, RK Vangala, … Blood 100 (2), 483-490, 2002
  4. Downregulation of c-Jun expression by transcription factor C/EBPĪ± is critical for granulocytic lineage commitment J Rangatia, RK Vangala, N Treiber, P Zhang, H Radomska, DG Tenen, … Molecular and cellular biology 22 (24), 8681-8694, 2002
  5. Downregulation of c-jun expression by transcription factor C/ebpalpha is critical for granulocytic lineage commitment: 569 J Rangatia, RK Vangala, N Treiber, P Zhang, DG Tenen, W Hiddemann, … Onkologie 25, 161, 2002
  6. Association of Ī³-glutamyl transferase with premature coronary artery disease M Ghatge, A Sharma, RK Vangala Biomedical reports 4 (3), 307-312, 2016
  7. Integrative bioinformatics analysis of genomic and proteomic approaches to understand the transcriptional regulatory program in coronary artery disease pathways RK Vangala, V Ravindran, M Ghatge, J Shanker, P Arvind, H Bindu, … PloS one 8 (2), e57193, 2013 
  8. BioParishodhana: A novel graphical interface integrating BLAST, ClustalW, primer3 and restriction digestion tools, RK Vangala, L Singh, RP Gupta Bioinformation 8 (13), 639,2012
  9. Modulation of clinically relevant pathways by post translation modification regulatory system in coronary artery disease RK Vangala, A Sharma, M Ghatge, Journal of Thrombosis and Haemostasis 13, 96, 2015
  10. In-silico to in-vivo proteomics of AML1-ETO interacting proteins in t (8; 21)-AML. RK Vangala, DG Tenen, W Hiddemann, G Behre, BLOOD 98 (11), 834A-834A, 2001